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“Proof-of-principle” that cell replacement therapy works for neurodegeneration has been reported, but only
using donor cells collected from fetal brain tissue obtained from surgical terminations of pregnancy. Surgical
terminations of pregnancy represent an increasingly limited supply of donor cells due to the tendency to-
wards performing medical termination in much of Europe. This imposes a severe constraint on further
experimental and clinical cell transplantation research. Therefore, we explore here the feasibility of using
medical termination tissue as a donor source. Products of conception were retrieved from surgical termina-
tions over the last 7 years and from medical terminations over the last 2.5 years. The number of collections
that yielded fetal tissue, viable brain tissue, and identifiable brain regions (ganglionic eminence, ventral
mesencephalon, and neocortex) were recorded. We studied cell viability, cell physiological properties, and
differentiation potential both in vitro and following transplantation into the central nervous system of rodent
models of neurodegenerative disease. Within equivalent periods, we were able to collect substantially greater
numbers of fetal remains from medical than from surgical terminations of pregnancy, and the medical termi-
nations yielded a much higher proportion of identifiable and dissectible brain tissue. Furthermore, we demon-
strate that harvested cells retain the capacity to differentiate into neurons with characteristics appropriate to
the region from which they are dissected. We show that, contrary to widespread assumption, medical termi-
nation of pregnancy-derived fetal brain cells represent a feasible and more readily available source of human
fetal tissue for experimental cell transplantation with the potential for use in future clinical trials in human
neurodegenerative disease.
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INTRODUCTION Empirically, the most successful transplants are taken
from the developing fetal brain close to the time of birth
of the specific populations of neurons to be transplantedCell replacement therapy involves the transplantation
of human fetal neuroblasts, obtained from elective ter- (18). At this stage the fate of the neurons is determined,
but they retain the developmental plasticity required tominations of pregnancy, into the brains of patients with
neurodegenerative diseases such as Parkinson’s (PD) integrate into the adult host environment. As a conse-
quence, tissue for transplantation must be harvestedand Huntington’s disease (HD) (17,27). Following trans-
plantation, implanted neuroblasts can mature, innervate within a specific gestational time window, and from the
precise region in the developing (fetal) brain that con-the surrounding neuropil, and contribute to the repair
of circuitry that has been damaged as a result of the tains the cells lost in the disease process. For example,
the dopamine containing neurons of the ventral mesen-degeneration. Several clinical trials for both PD and HD
have demonstrated proof-of-principle that cell replace- cephalon (VM), and the medium spiny neurons (MSNs)
developing within the fetal ganglionic eminence (GE—ment therapy can provide significant alleviation of symp-
toms in both conditions (1,19,22). putative striatum), for PD and HD, respectively, are born
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in the developing human brain towards the end of the ranged in age from 6 to 12 weeks pc, assessed by ultra-
sound measurements and confirmed using fetal morpho-first trimester [VM between 4 and 6 weeks (30) and GE
between 6 and 9 weeks postconception (pc), respectively metric data upon termination (8,14).
(26)].
Surgical Termination of PregnancyTo date, successful clinical trials have utilized fetal
tissue from surgical terminations of pregnancy (STOP). Tissue was collected via low-pressure aspiration us-
ing an Ipas manual vacuum aspirator and cannulae (Dur-We have been collecting tissue from STOP for cell re-
search and replacement therapies since 1997 using low- bin Clinic Sales, Middlesex, UK), with the aid of trans-
vaginal ultrasound. Following extraction, the products ofpressure transvaginal aspiration, with research ethical
committee approvals and with informed maternal con- conception were discharged into 50-ml centrifuge tubes
containing phosphate-buffered saline (PBS) supplementedsent (26). However, STOP tissue of suitable quality is
in limited supply due to several factors. Routine high- with glucose (0.6%) and heparin (5 µg/ml). Collected
material was transferred to a petri dish for inspection,pressure aspiration of fetal material does not yield iden-
tifiable brain tissue, so that successful collection re- and fetal parts transferred to a labeled 50-ml centrifuge
tube containing commercial hibernation medium (Hiber-quires engagement of an interested surgeon willing to
gain experience with low-pressure aspiration for collec- nate E, Invitrogen, Strathclyde, UK), and transported on
ice to the laboratory.tion of tissues for research use. Moreover, even low-pres-
sure aspiration results in substantial tissue fragmentation,
Medical Termination of Pregnancyvariable tissue quality, and difficulty in standardization of
collection and dissection procedures. The pressure on Mifepristone (200 mg) was administered orally and
the patient admitted to the gynecology ward 36–48 hsupply has been compounded by the requirement for
multiple fetal donors per patient in order to achieve sat- later, at which time 800 µg misoprostol was self-admin-
istered transvaginally. Following expulsion of the prod-isfactory cell numbers for some applications such as PD
neural transplantation (18), and more recently by the ucts of conception into a disposable cardboard recepta-
cle, fetal material was inspected by the nursing staff,move throughout Europe towards replacing STOP with
medical termination of pregnancy (MTOP) (5,7). MTOP was promptly transferred to a sterile 500-ml pot contain-
ing Hibernate E, and was stored at 4°C (usually for upis induced by administration of prostaglandin and anti-
progesterone drugs over a 48-h period, and the fetus is to 3 h but for a maximum of 12 h) before being trans-
ported on ice. The time at which the products of concep-usually passed during the following 8–12 h. In our own
center, this has resulted in STOP tissue becoming an tion were passed were recorded.
extremely scarce resource over the last 2–3 years.
Assessment of Gestational AgeCollection from spontaneous pregnancy loss has al-
ready been shown to be unsuitable for use in human The age of the fetus was estimated using three meth-
ods: i) ultrasound in the clinic, ii) crown–rump lengthtransplantation (3,11), and the use of MTOP material
was not previously pursued due to the assumption that (CRL) of the tissue in the laboratory, and iii) when the
fetal remains were fragmented (more common in STOPthe pharmacological agents used to induce termination
and the unspecified period of fetal death prior to expul- products), CRL was estimated using a formula based on
measurement of fetal limbs and other body parts (8,12).sion would adversely affect the viability of the collected
tissues. However, on the basis of experimental analyses,
Dissection and Preparation of Human CNS Tissuethese assumptions can be challenged, and here we dem-
onstrate good viability of MTOP-derived fetal brain tis- Tissues of interest (VM, GE, and cortex) were dis-
sected and tissue pieces were stored overnight in Hiber-sue in experimental cell transplantation. These new data
pave the way for detailed preclinical functional screen- nate E at 4°C for processing the following day. The
small number of embryos that were collected on the daying to assess the suitability of MTOP-derived fetal cells
for clinical neural transplantation studies. following termination were stored as whole embryos in
Hibernate E overnight at 4°C and dissected and pro-
MATERIALS AND METHODS cessed the following morning.
Human fetal tissue was collected following the guide-
Preparation of Cell Suspensionlines of the Polkinghorne (23) and Department of Health
(6) reports and with Bro Taf Local Research Ethics Dissected tissue pieces were incubated in 200 µl of
either TrypLE express (Invitrogen, Paisley, UK) or 0.1%Committee approval. Full consent was obtained from the
maternal donor, following consent for the termination, bovine trypsin (Worthington, UK) for 20 min at 37°C,
after which either benzonase (Merck, UK, 1:10,000) oras part of the MRC-sponsored, South Wales initiative
for transplantation (SWIFT) program. Fetal tissue DNAase (Sigma, UK, 0.01%) was added, and tissue in-
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cubated for a further 5 min at 37°C. VM tissue was then sensitization (for the GE grafts) (16), or by daily injec-
tions of cyclosporine (10 mg/kg, IP) commencing theplaced in 200 µl of fresh DNAase for trituration. GE
and cortical tissue were washed twice with Dulbecco’s day before transplantation until the day of sacrifice (VM
grafted animals), depending on the availability of pre-modified Eagle’s medium (DMEM/F-12, supplemented
with 1% PSF antibiotic-antimycotic), and then collected pared host animals at the time of tissue collection. For
neonatal inoculation host animals were inoculated IPby centrifugation at 100 × g for 3 min. The tissue was
resuspended in 200 µl DMEM/F12, and then triturated with human fetal CNS cells on the day of birth. Upon
reaching adulthood (220–250 g), rats received unilateralto produce a single cell suspension.
quinolinic acid lesions of the neostriatum (standard
Assessment of Cell Viability model of HD; n = 6), prior to receiving intracerebral
transplants of GE cells by stereotaxic injection into theCell suspensions from each region of interest were
counted in a hemocytometer using trypan blue exclu- neostriatum at 10 weeks of age. Rats receiving VM
grafts (n = 4) were “hemiparkinsonian,” having beension. The proportions of live and dead cells were re-
corded and viability expressed as the percentage of live unilaterally lesioned using the neurotoxin 6-OHDA, to
induce >95% dopamine depletion on one side of thecells in the suspension (21). Statistical analysis was car-
ried out with GenStat statistical software. Mean compar- brain. VM graft tissues were implanted into the dopa-
mine-depleted striatum on the lesioned side of the brain.ison was performed using a t-test.
To assess differentiation potential, dissociated cells
Transplantationwere plated onto 13-mm, poly-L-lysine-coated cover-
slips (0.1 mg/ml in distilled H2O) at a density of 1 × 105 Dissociated suspensions of VM cells were resuspended
in 0.01% DNAase in DMEM/F-12 at 300,000 cells/2 µl.cells/well. Cells were placed in the center of the cover-
slip in 30 µl of differentiation medium (standard me- GE cells were resuspended at 500,000 cells/2 µl.
Rats were anesthetised with gaseous 1.5–3% isoflur-dium plus 1% fetal calf serum and 2% B27) and allowed
to differentiate for either 3 days (VM cells) or 7 days ane in a 2:1 O2/NO mixture, mounted in a Kopf model
900 stereotaxic frame. All animals received 2 µl of cell(GE cells), and fed by replacing half the medium with
fresh medium every 3 days. Cells were then washed us- suspension injected via a 10-µl glass microsyringe tar-
geted at the right dorsal striatum, coordinates: anterioring PBS and prepared for immunocytochemistry by fixa-
tion with 4% paraformaldehyde in 0.1 M PBS for 20 in front of bregma, AP = +0.6 mm; lateral to the midline,
L = −2.6 mm; vertical below dura, V = −5.5 and −4.5min. For calcium imaging the cells were maintained in
differentiation media for up to 24 days. mm (1 µl at each depth); with the nose bar set −2.3 mm
below the interaural line. Graft tissue was injected overIndirect fluorescent immunocytochemistry was per-
formed using standard protocols (15) with primary anti- 2 min, with a further 3 min allowed for diffusion before
the needle was slowly withdrawn, the wound cleanedbodies directed against β-III tubulin (1:1000, Sigma),
glial fibrillary acidic protein (GFAP, 1:1000, DAKO), and sutured, and the animal allowed to recover. All ani-
mals received a 5-ml SC injection of 0.18% sodiumdopamine- and cAMP-regulated neuronal phosphopro-
tein (DARPP-32, 1:1000, Chemicon) and the dopamine chloride with 4% glucose (Aqupharm, Dunnington,
York) to avoid dehydration. Paracetamol analgesia wasmarker tyrosine hydroxylase (TH, 1:1000, Chemicon),
and appropriate fluorescent-labeled secondary antibod- administered via the water supply for 2 days following
operation.ies. Fluorescent staining was visualized on a Leica DRMB
microscope, and cell counts performed at 400× magnifi-
Posttransplant Immunohistochemistrycation. For eachcoverslip, at least five random fields
were counted. Pseudocolor fluorescent images were ob- Animals were sacrificed either 4 weeks (VM trans-
plants) or 12 weeks posttransplantation; all animals weretained using Openlab 2.1 image analysis software.
sacrificed by barbiturate overdose (Euthatal, Merial Ani-
Experimental Animals mal Health, Harlow, UK) and perfused via the ascending
aorta with 50–100 ml 0.1 M PBS (pH 7.5) followed byAnimal experiments were performed in full compli-
ance with local ethical guidelines and approved animal 250–300 ml 4% paraformaldehyde in PBS. Brains were
removed, cryoprotected in 20% sucrose, and sectionedcare according to the UK Animals (Scientific Proce-
dures) Act 1986. Sprague-Dawley (Harlan UK) rats at 40 µm on a freezing sledge microtome. A 1:6 series
of free-floating sections was stained immunohistochemi-were used as graft recipients, housed four per cage in a
12 h:12 h light/dark cycle, and with access to food and cally using the biotin-streptavidin-horseradish peroxi-
dase method. Primary antibodies against the followingwater ad libitum.
Immunosuppression of animals receiving xenografts antigens were used: human nuclear antigen (HuNu, 1:
500, Chemicon), DARPP-32, (1:1,000, Chemicon), andof human fetal cells was achieved either by neonatal de-
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TH (1:1000, Chemicon). Stained sections were in- correspondingly increased. Consequently, in the last 2
years (January 2007 to March 2009) we have recruitedspected and photographed using a Leica DRMB micro-
scope with an Optronics Magnafire digital camera, un- 300 cases from the MTOP list. The following analysis
is based on a comparison of the first 300 cases collectedder bright field illumination.
by each method, a milestone reached at the same time
Quantification of Graft Parameters for both procedures in March 2009.
Graft volume and cell number calculations were
Tissue Collectionbased on HuNu staining and determined using the Olym-
pus CASTgrid stereology system on a 1:12 series. The Table 1 highlights the numbers of cases that were
analyzed and identifies the differences between STOPfractionator method was used that samples a fraction of
the total cells (i.e., the fraction of the area samples, the and MTOP tissue collections in relation to the number
of useable tissues harvested from the two sources. Offraction of sections stained, and the ratio between the
section thickness and the dissector from which they the 600 cases consented, 17.6% STOP and 22% MTOP
withdrew, either from the termination itself (in mostwere counted) (29). Graft volume was calculated for
each experimental group. cases) or from consent to donation. There were 13.7%
MTOP donations lost as a result of the hospital protocol
Calcium Imaging in which patients under 7 weeks pc were allowed home
to complete the procedure if expulsion had not takenCells were loaded with 6 µM fura-2 acetoxymethyl
ester (Molecular Probes, Eugene, OR, USA) diluted in place on the ward during the course of the day. A small
percentage of samples were lost at collection (0.8% andnormal DMEM/F-12, for 30 min at 37°C. Cells were
placed in a perfusion chamber mounted upon an Olym- 10% STOP and MTOP, respectively) for a variety of
less common reasons, including: nonexpulsion of the fe-pus IX71inverted microscope equipped with a Cairn
monochromator-based fluorescence system (Cairn In- tus requiring emergency surgery; failure in labeling and
quality control; and transportation difficulties. Therestruments, Faversham, Kent, UK) and were continuously
superfused with a solution containing in (mM) 135 were 9.3% STOP and 29.6% MTOP samples estimated
on collection to be outside the inclusion age range,NaCl, 5 KCl, 1.25 CaCl2, 1.2 MgCl2, 5 HEPES, 10 glu-
cose, pH 7.4. Fura-2 was alternately excited at 340 and which was less than 10 weeks pc, and so were not taken
for subsequent analyses.380 nm. Images at 510 nm were acquired at 0.2 Hz by
a slow-scan CCD camera (Kinetic Imaging Ltd, Notting- Of the samples collected, 43% STOP and 87.5%
MTOP contained identifiable fetal parts from whichham, Notts UK). Following background subtraction,
emission ratios (340/380) were calculated off-line using measurements could be taken. The age of the fetus was
estimated independently, based on the Evtouchenkothe Andor IQ 1.3 software package (Andor Technology,
Belfast, UK). γ-Aminobutyric acid (GABA) (50 µM), equation (8), which was found to correlate closely with
the age as estimated from ultrasound measurement in50 µM kainate, 50 µM α-amino-3-hydroxyl-5-methyl-4-
isoxazole-propionate (AMPA), 50 µM N-methyl-D-aspar- vivo (r = 0.910, df = 126, p < 0.001). This is directly
comparable to the correlation, r = 0.875, previously re-tic acid (NMDA), and 100 µM L-glutamic acid (all
Sigma-Aldrich, Poole, UK) were rapidly (20 ms solution ported for STOP (26).
A substantially greater proportion of MTOPs yieldedexchange) applied locally to the cells using gravity-
driven perfusion through a multibarrel motorized solu- identifiable CNS tissue than did STOPs (94% MTOP
compared to 39.6% STOP). Furthermore, in mosttion exchanger (Bio Logic Rapid Solution Changer
RSC-100; Molecular Kinetics, Pullman, WA, USA). A MTOP, the CNS tissue included brain, whereas a large
proportion of the STOP yielded spinal cord with nodepolarizing solution (in mM) 90 NaCl, 50 KCl, 1.25
CaCl2, 1.2 MgCl2, 5 HEPES, 10 glucose (pH 7.4) was identifiable brain tissue. This is likely to be related to
the greater fragmentation seen in STOP. Specifically,used to determine neuronal excitability.
STOP samples yielded fewer than 5% (5/134) intact fe-
RESULTS tuses, with most samples being significantly fragmented.
By contrast, the fetus was entirely intact and in someThe SWIFT program commenced in October 2003
and by the end of the period of study in March 2009, cases still within the amniotic sac in more than 90%
(114/120) of MTOP. As a consequence, we were able300 patients undergoing STOP consented to donate em-
bryos to the program. However, since 2007, in Cardiff accurately to dissect cortex, VM, and GE from the ma-
jority of cases (see Table 1). Figure 1 presents the sameas in the rest of the UK, the number of early termina-
tions by STOP has declined markedly. Both the numbers data, expressed as a percentage of total MTOP or STOP
consented in order to illustrate the ultimate yield of spe-and the proportion of early terminations by MTOP have
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Table 1. Differences Between STOP and MTOP Tissue Collections in Relation
to the Number of Useable Tissues Harvested From the Two Sources
STOP MTOP
Total number consented 300 300
Subsequently withdrew 53/300 (17.6%) 66/300 (22%)
Sent home to complete n/a 32/234 (13.7%)
Not collected or missed by ward* 2/247 (0.8%) 20/202 (10%)
Too large for purpose 23/245 (9.3%) 54/182 (29.6%)
Measurable fetal parts 96/222 (43%) 112/128 (87.5%)
No brain tissue 134/222 (60%) 8/128 (6.2%)
CNS 88/222 (39.6%) 120/128 (94%)
Ctx 64/88 (73%) 114/120 (95%)
GE 40/88 (45%) 112/120 (93%)
VM 22/88 (25%) 103/120 (86%)
A total of 600 patients have consented to donate tissue for use in the SWIFT program.
Over time the actual number of tissue samples is much lower and the table highlights where
samples were lost. Where samples were over the 10 week pc age at the time of passing the
tissue was deemed too large for our purposes and so was not included for analyses. The
last three rows in the table show the percentage of tissue samples from which regions of
interest were obtained and are expressed as a percentage of all collected samples as opposed
to a percentage of all that consented. STOP, surgical termination of pregnancy; MTOP,
medical termination of pregnancy; Ctx, cortex; VM, ventral mesencephalon; GE, ganglionic
eminence.
*Missed samples include those not collected by the team, patients who failed the MTOP
requiring evacuation of retained products, or those who were not identified as South Wales
initiative for transplantation (SWIFT) on the ward and subsequently not collected.
Figure 1. The number of cases where identifiable tissue was retrievable from both medical (MTOP; light gray) and surgical
terminations of pregnancy (STOP; dark gray). The dissection accuracy from MTOP tissue was far greater than that from STOP
tissue due to the fragmented nature of STOP tissue.
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cific brain regions of interest from the two TOP meth- from the GE-expressed DARPP-32 as a marker of
MSNs (Fig. 3B). The percentage of total cells that areods, indicating the much higher yields derived from
MTOP compared to STOP. DARPP-32 positive in cultures is in the range of 60–
75%, which represents 75–90% of all neurons from pri-
Cell Viability mary WGE tissue in the range of 20–30 mm CRL. This
is comparable to what we have reported previously fromThe utility of the tissue, whether for research or ther-
apy, depends on not only supply but also the viability STOP-derived GE tissues. In the case of VM tissue the
number of TH-positive neurons from each VM was cal-of the tissue obtained. Cell viability was assessed in all
dissociated CNS tissues by trypan blue exclusion. Over- culated according to the age of the tissue piece. It was
found that the number of TH neurons ranged fromall, the viability of MTOP neurons was somewhat lower
than that derived for STOP [means ± SEM, 75.73 ± 50,000 to 200,000 cells per VM, which is in accordance
to previously reported studies using STOP-derived tis-1.24% vs. 85.28 ± 0.89%, respectively, t(174) = 5.399,
p < 0.0001] (Fig. 2). Previous experience has indicated sue. Secondly, we have used calcium imaging as a mea-
sure of neuronal differentiation and health, and findthat an initial trypan blue exclusion higher than 80%
[(22) and our unpublished results] results in good cell comparable profiles of functional cellular activity from
the two tissue sources (Figs. 4 and 5). Specifically, atviability both in vitro and in vivo. Forty-nine percent of
MTOP samples and 85% of STOP samples exceeded 24 days in vitro (DIV) cells derived from both MTOP
(Fig. 4A) and STOP (Fig. 4B) responded to the nonse-this criterion, but the lower proportion of viable samples
from MTOP was markedly offset by the much higher lective depolarizing stimulus of 50 mM extracellular
KCl (high K+ 1 with a rise in intracellular calcium con-rate of retrieval of brain areas of interest (e.g., 58/103
VM from MTOP vs. only 9/22 VM from STOP, from a centration ([Ca2+]i). The mean rises in [Ca2+]i in the cell
populations derived from MTOP and STOP were almosttotal of 300 initial consents in each case).
identical at around 30% above baseline (Fig. 4C). The
Characterization of MTOP Tissue mean increases in [Ca2+]i that were evoked in the two
populations by NMDA, GABA, AMPA, kainite, andIn addition to trypan blue evaluation of viability of
the freshly prepared cells, we evaluated the long-term glutamate were, again, almost indistinguishable (Fig.
4C), with NMDA evoking the most robust rises in bothviability of MTOP tissue for survival and differentiation
by three additional criteria (Figs. 3–5). First, MTOP- cases (Fig. 4A, B, C). Furthermore, after 15 min of re-
cording, and following five further applications of ago-derived tissue was seen to differentiate into appropriate
populations of neurons when cultured in vitro. In partic- nists, the responses to a subsequent depolarizing stimu-
lus (high K+ 2) evoked increases in [Ca2+]i, which wereular, cultures derived from VM expressed TH, a marker
of surviving dopamine neurons (Fig. 3A) and tissue not significantly diminished from those evoked by the
Figure 2. The viability of the tissue (one data point per fetus) was assessed using a trypan blue exclusion assay. The trend line
shows the proportion of tissue with viability of 80% and above; this is the minimum viability currently accepted for use in clinical
transplantation paradigms. For MTOP tissue 58% were above the 80% cut-off whereas for STOP tissue the percentage is much
higher at 82%.
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Figure 3. Photomicrographs of immunohistochemical labeling for (A) tyrosine hydroxylase (TH;
red) in MTOP-derived 3-day in vitro differentiated ventral mesencephalon (VM) cells, and (B)
dopamine- and cAMP-regulated neuronal phosphoprotein (DARPP-32; green) 7-day in vitro differ-
entiated MTOP-derived ganglionic eminence (GE) cells, highlighting the potential of MTOP-
derived tissue to differentiate in tissue culture into neurons specific to its region of origin. Blue
represents Hoechst staining. Immunohistochemical staining of (C) DARPP-32 (green)/human nu-
clear antigen (HuNu; red)-positive neurons within the graft 12 weeks posttransplantation. At this
survival time DARPP-32-positive neurons are seen principally at the periphery of the graft. (D)
TH-positive neurons within the graft 4 weeks posttransplantation. Inset: Higher power of TH-
positive neurons. Scale bar: 50 µm.
first depolarizing stimulus (Figs. 4C, 5). This indicates mean graft volume was 0.52 mm3 in the case of GE-
grafted tissue (STOP graft volume mean = 0.69 mm3)that the smaller responses seen upon application of ago-
nists were not a result of any type of experimentally and 0.68 mm3 in VM tissue grafts. However, the number
of mature cells within the graft was somewhat differentinduced, time-dependent dysregulation in calcium ho-
meostasis per se. The cell-by-cell analyses shown in Fig- for the two tissue sources with a mean of 16 cells/mm3
DARPP-32-positive cells in the GE grafts compared toure 5, which individually plot the responses evoked by
the first depolarizing stimulus against the responses 7173cells/mm3 for VM grafts. The low number of ma-
ture DARPP-32-positive cells in the GE grafts is mostevoked by each individual agonist (and second depolar-
izing stimulus) of each cell, indicate that MTOP and likely due to short survival time, as it has been shown
previously that such grafts require long time points inSTOP essentially respond similarly to this range of ago-
nists. Thus, the regression lines of the increases in vivo for full maturation to take place.
[Ca2+]i evoked by high K+ 1 versus high K+ 2, GABA,
DISCUSSIONAMPA, kainite, and L-glutamate are not significantly
different from each other. The shift from STOP to MTOP in recent years has
imposed severe limitations on STOP as a source of tis-Thirdly, both VM and GE cell suspensions survived
transplantation into the relevant animal lesion models, sue for both experimental and clinical studies of cell re-
placement therapy in CNS neurodegeneration. Contraryyielding large healthy grafts in all animals, with DARPP-
32-positive (Fig. 3C) or TH-positive neurons (Fig. 3D), to presupposition, we have here identified MTOP tissue
as a viable source of human fetal cells for transplanta-respectively, directly comparable to previous reports of
human fetal xenografts derived from STOP (15). The tion studies in neurodegenerative disorders such as PD
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Figure 4. Intracellular calcium concentration [Ca2+]i rises evoked by depolarizing stimuli and neu-
rotransmitter applications. Rises in intracellular calcium in exemplar, individual cells derived from
MTOP (A) and STOP (B) fetal GE tissue during brief applications of depolarizing solutions (high
K+ 1 and high K+ 2), 50 µM γ-aminobutyric acid (GABA), 50 µM kainate, 50 µM α-amino-3-
hydroxyl-5-methyl-4-isoxazole-propionate (AMPA), 50 µM N-methyl-D-aspartic acid (NMDA),
and 100 µM L-glutamic acid. Relative [Ca2+]i is reported as the ratio of Fura-2 emission intensities
at 510 nm following excitation of the probe sequentially at 340 nm and 380 nm and is plotted as
relative units (R.U.) versus time. Agonists were applied for the durations indicated by the bars
above each trace. (C) Mean ± SEM rises in [Ca2+]i in response to each agonist and high K+ solu-
tions plotted as percentage increase in fluorescence above baseline [n = 230 MTOP (open bars),
n = 88 STOP (filled bars).
and HD. The process of a MTOP is undertaken over a but implantation of unwanted tissues can have detrimen-
tal consequences (10,20).48-h period, raising the possibility that the fetus could
die at any time during that period. Thus, the concern that A crucial requirement of transplanted cells is that
they are able to differentiate into the precise phenotypethe CNS cells could be subject to a prolonged period
of anoxia, rendering them nonviable for transplantation lost to the disease process. We show here for both VM
and GE tissues that this can be achieved in vitro. Thepurposes, is fully plausible. Although a proportion of
MTOP collections do indeed show lower viability than number of region specific neurons (TH and DARPP-32)
generated from respective brain regions was comparableSTOP cells, the vast majority were over 50% viable, and
58% were in the acceptable range (≥80% viability). In to that previously reported for STOP-derived tissue (4,14).
Where both STOP and MTOP GE tissues were di-addition, it may be that a broader viability range proves
to be acceptable, and experimental studies are ongoing rectly compared by calcium imaging, it was found that
the majority of the neurons responded to all of the ago-to assess this question. Importantly, the greater variance
in viability was more than off-set by the substantially nists used, a good indicator that they are functional neu-
rons. NMDA, AMPA, kainite, and L-glutamate are allgreater number of MTOP cases that could be collected
over a given period of time in addition to the increased linked with striatal neuron function. The remarkable
similarities in the responsiveness of MTOP and STOPnumber of intact brain retrievals from the MTOP cases
(allowing easy identification of particular brain regions). neurons suggest that neuroblasts derived from both
sources survived the procurement process equally wellThis is of importance because not only is the accuracy
of dissection an imperative for a successful transplant, and were able to develop into mature and functionally
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active neurons. Of particular note are the responses to responses over time in vitro, which should give insight
into such questions in the near future.GABA. It is well documented that fetal, in contrast to
adult, central neurons respond to GABA by depolariz- Following transplantation into the appropriate animal
models, we also see evidence of differentiation appro-ing. This so-called fetal excitatory response of GABAA
receptor activation is due to the fact that the equilibrium priate to the area from which the donor tissue was de-
rived. Due to the scarcity of useable STOP tissue in re-potential of chloride (the permeant ion of GABAA recep-
tor channels) of fetal neurons is more positive than the cent times, these grafts have been compared to grafts of
STOP-derived striatal tissue performed in this laboratoryfetal resting membrane potential (2). That both MTOP
and STOP cells respond to GABA by increasing [Ca2+]i using identical conditions (26) or previously published
data (4,13,14,28). Although a direct comparison woulddemonstrates that GABA evokes a depolarization of a
magnitude sufficient to cause voltage-activated calcium have been more satisfactory, the paucity of available
STOP tissue is likely to be a continuing situation, andinflux, and indicates that both MTOP- and STOP-derived
cells in vitro still express a fetal phenotype, even after indeed is the rationale for this study in the first place.
The low numbers of DARPP-32-positive cells are gener-24 DIV. The responses to NMDA are interesting in that
MTOP cells demonstrate a slightly larger population ally what is found at this survival time point and it is
likely that longer periods posttransplantation are neededthan STOP cells, which are clearly excitable (in that
they respond to high K+ 1) but do not respond robustly to allow full maturation of GE grafts.
We have shown here that MTOP-derived tissue is ato NMDA (Fig. 5, upper central panel). Currently, we
have no explanation for this slight difference, but be- viable source of cells for experimental transplantation
studies in HD and PD. The use of such tissue overcomescause the regression lines (MTOP vs. STOP) are identi-
cal if these particular cells are excluded from the analy- the logistical issues associated with the present and fu-
ture use of STOP-derived tissue. The greater spread insis, it appears that there is a small subpopulation of cells
(ca. 10%) from MTOP that are not present in STOP the viability of the MTOP-derived tissue is overcome by
the greater supply of this tissue. Previously, we havecells; whether this subpopulation is selectively ablated
in the STOP preparation or whether it is an artifact of reported on infectious data collected from STOP tissue
(9) and similar data collection is now ongoing forthe MTOP procedure is currently a matter of conjecture.
However, work is ongoing to characterize further these MTOP tissue with a view to this tissue being used for
Figure 5. Cell-by-cell analysis of intracellular calcium concentration [Ca2+]i rises evoked by each individual neurotransmitter. Rises
in [Ca2+]i evoked by the second depolarizing stimulus (high K+ 2) and each agonist (50 µM GABA, 50 µM kainate, 50 µM AMPA,
50 µM NMDA, and 100 µM L-glutamic acid) are plotted against the rises in [Ca2+]i evoked in the same cell by the first depolarizing
stimulus (high K+ 1). As in Figure 4C, relative [Ca2+]i was assayed as the ratio of Fura-2 emission intensities at 510 nm following
excitation of the probe sequentially at 340 and 380 nm and is plotted as percentage increase in fluorescence above baseline [n =
230 MTOP (open symbols), n = 88 STOP (filled symbols)].
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(RU 486) and oral or vaginal misoprostol. N. Engl. J.sue is very low (9) and theoretically that from MTOP
Med. 332(15):983–987; 1995.
tissue may be lower, as the fetus is frequently retrieved 8. Evtouchenko, L.; Studer, L.; Spenger, C.; Dreher, E.;
within the amniotic sac. Seiler, R. W. A mathematical model for the estimation of
human embryonic and fetal age. Cell Transplant. 5:453–The data presented here suggest that MTOP tissue
464; 1996.may be as suitable as STOP tissue for future clinical
9. Farrington, M.; Wreghitt, T. G.; Lever, A. M. L.; Dunnett,application in neurodegenerative disease, and indeed S. B.; Rosser, A. E.; Barker, R. A. Neural transplantation
may ultimately prove to be superior in that it can be in Huntington’s disease: The NEST-UK donor tissue mi-
more readily and reliably dissected. The suitability for crobiological screening program and review of the litera-
ture. Cell Transplant. 15(4):279–294; 2006.clinical application will, of course, require further stud-
10. Folkerth, R. D.; Durso, R. Survival and proliferation ofies to demonstrate functional benefit of MTOP-grafted
nonneural tissues, with obstruction of cerebral ventricles,tissue in disease models. Functional benefit has been in a parkinsonian patient treated with fetal allografts. Neu-demonstrated previously for human STOP-derived VM rology 46(5):1219–1225; 1996.
tissue (24,25), but it is interesting to note that there have 11. Hainline, B. E.; Padilla, L. M.; Chong, S. K.; Heifetz,
S. A.; Palmer, C.; Zhou, F. C. Fetal tissue derived frombeen little functional data to date for GE-grafted ani-
spontaneous pregnancy losses is insufficient for humanmals, in part due to fall in STOP tissue availability over
transplantation. Obstet. Gynecol. 85(4):619–624; 1995.recent times. 12. Hurelbrink, C. B.; Armstrong, R. J.; Barker, R. A.;
ACKNOWLEDGMENTS: The study was funded by grants Dunnett, S. B.; Rosser, A. E. Hibernated human fetal stria-from the Medical Research Council, the UK Stem Cell Foun- tal tissue: Successful transplantation in a rat model of
dation, the Welsh Office of Research and Development, and Huntington’s disease. Cell Transplant. 9(6):743–749;
the Welsh Assembly Government. S.V.P., A.W.H., and U.M.W. 2000.
were funded by studentships from the Medical Research Coun- 13. Hurelbrink, C. B.; Barker, R. A. Migration of cells from
cil and the German Studienstiftung, respectively. C.M.K. and primary transplants of allo- and xenografted foetal striatal
S.V.P. are joint first authors. S.B.D., A.E.R., and N.N.A. un- tissue in the adult rat brain. Eur. J. Neurosci. 21(6):1503–
dertook study design and supervised the project. D.W., C.S., 1510; 2005.
and R.P. were involved in the consent and clinical collection 14. Hurelbrink, C. B.; Tyers, P.; Armstrong, R. J.; Dunnett,
of tissues. C.M.K., S.V.P., E.M.T., A.W.H., E.L.L., A.L.B., S. B.; Barker, R. A.; Rosser, A. E. Long-term hibernation
U.M.W., and P.J.K. undertook different aspects of the cell and of human fetal striatal tissue does not adversely affect its
tissue processing, transplantation, and experimental analyses differentiation in vitro or graft survival: Implications for
of the tissue. Statistical analysis was done by C.M.K., S.V.P., clinical trials in Huntington’s disease. Cell Transplant.
and S.B.D.. C.M.K., S.V.P., A.E.R., and S.B.D. drafted the 12(7):687–695; 2003.
manuscript and all authors reviewed, revised, and agreed on 15. Kelly, C. M.; Precious, S. V.; Penketh, R.; Amso, N.;
the submitted version. Dunnett, S. B.; Rosser, A. E. Striatal graft projections are
influenced by donor cell type and not the immunogenicREFERENCES background. Brain 130(5):1317–1329; 2007.
16. Kelly, C. M.; Precious, S. V.; Scherf, C.; Penketh, R.;1. Bachoud-Levi, A. C.; Gaura, V.; Brugieres, P.; Lefaucheur,
J. P.; Boisse, M. F.; Maison, P.; Baudic, S.; Ribeiro, Amso, N. N.; Battersby, A.; Allen, N. D.; Dunnett, S. B.;
Rosser, A. E. Neonatal desensitization allows long-termM. J.; Bourdet, C.; Remy, P.; Cesaro, P.; Hantraye, P.;
Peschanski, M. Effect of fetal neural transplants in pa- survival of neural xenotransplants without immunosup-
pression. Nat. Methods 6(4):271–273; 2009.tients with Huntington’s disease 6 years after surgery: A
long-term follow-up study. Lancet Neurol. 5(4):303–309; 17. Lane, E. L.; Handley, O. J.; Rosser, A. E.; Dunnett, S. B.
Potential cellular and regenerative approaches for the2006.
2. Ben-Ari, Y. Excitatory actions of GABA during develop- treatment of Parkinson’s disease. Neuropsychiatr. Dis.
Treat. 4(5):835–845; 2008.ment: The nature of the nurture. Nat. Rev. Neurosci. 3(9):
728–739; 2002. 18. Lindvall, O.; Bjorklund, A. Cell therapy in Parkinson’s
disease. NeuroRx 1(4):382–393; 2004.3. Branch, D. W.; Ducat, L.; Fantel, A.; Low, W. C.; Zhou,
F. C.; Dayton, D. H.; Gill, 3rd, T. J. Suitability of fetal 19. Lindvall, O.; Rehncrona, S.; Brundin, P.; Gustavii, B.;
Astedt, B.; Widner, H.; Lindholm, T.; Bjorklund, A.;tissues from spontaneous abortions and from ectopic preg-
nancies for transplantation. Human Fetal Tissue Working Leenders, K. L.; Rothwell, J. C. Neural transplantation in
Parkinson’s disease: The Swedish experience. Prog. BrainGroup. JAMA 273(1):66–68; 1995.
4. Brundin, P.; Strecker, R. E.; Widner, H.; Clarke, D. J.; Res. 82:729–734; 1990.
20. Mamelak, A. N.; Eggerding, F. A.; Oh, D. S.; Wilson, E.;Nilsson, O. G.; Astedt, B.; Lindvall, O.; Bjorklund, A.
Human fetal dopamine neurons grafted in a rat model of Davis, R. L.; Spitzer, R.; Hay, J. A.; Caton, 3rd, W. L.
Fatal cyst formation after fetal mesencephalic allograftParkinson’s disease: Immunological aspects, spontaneous
and drug-induced behaviour, and dopamine release. Exp. transplant for Parkinson’s disease. J. Neurosurg. 89(4):
592–598; 1998.Brain Res. 70(1):192–208; 1988.
5. Department of Health. Abortion statistics, England and 21. Marchenko, S.; Flanagan, L. Counting human neural stem
cells. J. Vis. Exp. (7):262; 2007.Wales: 2007. London, UK: Department of Health; 2007.
6. Department of Health. Guidance on the supply of fetal 22. Mendez, I.; Vinuela, A.; Astradsson, A.; Mukhida, K.;
Hallett, P.; Robertson, H.; Tierney, T.; Holness, R.;tissue for research diagnosis and therapy. London, UK:
Department of Health; 1995. Dagher, A.; Trojanowski, J. Q.; Isacson, O. Dopamine
neurons implanted into people with Parkinson’s disease7. el-Refaey, H.; Rajasekar, D.; Abdalla, M.; Calder, L.;
MEDICAL TERMINATIONS OF PREGNANCY FOR CELL REPAIR 513
survive without pathology for 14 years. Nat. Med. 14(5): Thornton, S.; Hutchinson, H.; Dunnett, S. B. Staging and
preparation of human fetal striatal tissue for neural trans-507–509; 2008.
23. Polkinghorne, J. Review of the guidance on the research plantation in Huntington’s disease. Cell Transplant. 12(7):
679–686; 2003.use of fetuses and fetal material. London, UK: Her Majes-
ty’s Stationary Office; 1989. 27. Rosser, A. E.; Dunnett, S. B. Cell transplantation for Hun-
tington’s disease. Lancet Neurol. 5(4):284–285; 2006.24. Redmond, Jr., D. E.; Elsworth, J. D.; Roth, R. H.; Leranth,
C.; Collier, T. J.; Blanchard, B.; Bjugstad, K. B.; Samul- 28. Stromberg, I.; Bygdeman, M.; Goldstein, M.; Seiger, A.;
Olson, L. Human fetal substantia nigra grafted to the do-ski, R. J.; Aebischer, P.; Sladek, Jr., J. R. Embryonic sub-
stantia nigra grafts in the mesencephalon send neurites to pamine-denervated striatum of immunosuppressed rats:
Evidence for functional reinnervation. Neurosci. Lett.the host striatum in non-human primate after overexpres-
sion of GDNF. J. Comp. Neurol. 515(1):31–40; 2009. 71(3):271–276; 1986.
29. West, M. J. Stereological methods for estimating the total25. Redmond, Jr., D. E.; Vinuela, A.; Kordower, J. H.; Isac-
son, O. Influence of cell preparation and target location number of neurons and synapses: Issues of precision and
bias. Trends Neurosci. 22(2):51–61; 1999.on the behavioral recovery after striatal transplantation of
fetal dopaminergic neurons in a primate model of Parkin- 30. Winkler, C.; Kirik, D.; Bjorklund, A. Cell transplantation
in Parkinson’s disease: How can we make it work? Trendsson’s disease. Neurobiol. Dis. 29(1):103–116; 2008.
26. Rosser, A. E.; Barker, R. A.; Armstrong, R. J.; Elneil, S.; Neurosci. 28(2):86–92; 2005.
Jain, M.; Hurelbrink, C. B.; Prentice, A.; Carne, C.;

